[
  {
    "title": "Slate starts up with $130M and a headache drug from China",
    "link": "https://www.biopharmadive.com/news/slate-medicines-migraine-biotech-pacap-china-dartsbio/812859/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-24T12:30:00.000Z",
    "summary": "The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines."
  },
  {
    "title": "STAT+: Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church",
    "link": "https://www.statnews.com/2026/02/24/epstein-cell-line-george-church-harvard-personal-genome-project/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "Exclusive: Harvard geneticist George Church knew more about Jeffrey Epstein's activities than he has previously said, before accepting new donations from the sex offender."
  },
  {
    "title": "STAT+: Digital twins, the holy grail of preventative health, are still only a ‘Frankensteinian proof of principle’",
    "link": "https://www.statnews.com/2026/02/24/digital-twins-health-care-hype-reality/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "AI advances and new data on genomics, patient outcomes, and drug performance have pushed the idea of “digital twins” closer to reality than ever before."
  },
  {
    "title": "STAT+: New treatment approach could give IBD patients hope, and be a bonanza for drugmakers",
    "link": "https://www.statnews.com/2026/02/24/ibd-combination-therapy-race-abbvie-lilly-pfizer-merck-jnj/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "New treatment approaches could give inflammatory bowel disease patients hope, and make drugmakers a bonanza."
  },
  {
    "title": "Opinion: It’s time for a new era of advocacy for physicians",
    "link": "https://www.statnews.com/2026/02/24/doctors-advocacy-aafp-lobbying-congress/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "“Physicians are, by nature and necessity, advocates,” writes Sarah C. Nosal, president of the American Academy of Family Physicians."
  },
  {
    "title": "Opinion: STAT+: Optum CMO: Doctors must take responsibility for patient outcomes",
    "link": "https://www.statnews.com/2026/02/24/medicare-advantage-plans-doctors-risk-outcomes-optum-research/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "“To critics of Medicare Advantage, these results scramble the debate,” writes Optum CMO Ken Cohen."
  },
  {
    "title": "STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding",
    "link": "https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T01:14:06.000Z",
    "summary": "In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line."
  },
  {
    "title": "FDA fleshes out new roadmap for testing personalized therapies",
    "link": "https://www.biopharmadive.com/news/fda-guidance-personalized-therapies-rare-diseases-hhs/812890/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T22:03:00.000Z",
    "summary": "At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases."
  },
  {
    "title": "STAT+: Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments",
    "link": "https://www.statnews.com/pharmalot/2026/02/23/bayer-jnj-prostate-cancer-false-advertising-lawsuit/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T19:34:43.000Z",
    "summary": "Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote its drug as more effective."
  },
  {
    "title": "Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study",
    "link": "https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T17:22:33.000Z",
    "summary": "Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound."
  },
  {
    "title": "STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications",
    "link": "https://www.statnews.com/2026/02/23/fda-rare-disease-new-guidelines-plausible-mechanism-pathway/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T16:35:07.000Z",
    "summary": "The FDA expects a flood of applications for a new \"plausible mechanism pathway\" for approval of bespoke gene-editing treatments."
  },
  {
    "title": "FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-23T16:32:48.000Z",
    "summary": "The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety…"
  },
  {
    "title": "STAT+: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle",
    "link": "https://www.statnews.com/2026/02/23/medicare-ai-modernization-project-ohiohealth-antitrust-battle-health-care-inc/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T16:18:05.000Z",
    "summary": "Would you trust AI to help you pick your Medicare plan?"
  },
  {
    "title": "Ralph Abraham, No. 2 official at CDC, abruptly steps down",
    "link": "https://www.statnews.com/2026/02/23/ralph-abraham-cdc-resigns/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T14:58:09.000Z",
    "summary": "The No. 2 official at the CDC has resigned, adding to the drama and chaos surrounding the agency's leadership."
  },
  {
    "title": "STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study",
    "link": "https://www.statnews.com/2026/02/23/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T14:37:34.000Z",
    "summary": "And other biotech news brought to you by The Readout"
  },
  {
    "title": "STAT+: People with intellectual and development disabilities have higher rates of anxiety, depression",
    "link": "https://www.statnews.com/2026/02/23/health-news-anxiety-depression-and-intellectual-disabilities/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T14:19:41.000Z",
    "summary": "And other health news from the Morning Rounds newsletter"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more",
    "link": "https://www.statnews.com/pharmalot/2026/02/23/pharma-lobbying-novo-obesity-merck-gilead-tariffs/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T13:57:18.000Z",
    "summary": "Pharmaceutical companies are boosting their spending on lobbying firms with connections to the White House"
  },
  {
    "title": "Merck to split cancer, specialty drug businesses in leadership shakeup",
    "link": "https://www.biopharmadive.com/news/merck-cancer-specialty-split-business-pharmaceuticals/812805/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T13:38:28.000Z",
    "summary": "Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines."
  },
  {
    "title": "STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval",
    "link": "https://www.statnews.com/2026/02/23/gossamer-drug-fails-lung-disease-study-will-still-seek-fda-approval/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T13:00:00.000Z",
    "summary": "Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial."
  },
  {
    "title": "Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy",
    "link": "https://www.biopharmadive.com/news/gilead-arcellx-acquire-multiple-myeloma-cell-therapy-anito-cel/812798/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T12:49:00.000Z",
    "summary": "The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said."
  },
  {
    "title": "STAT+: Gilead to buy Arcellx in nearly $8B deal",
    "link": "https://www.statnews.com/2026/02/23/gilead-arcellx-acquisition-car-t-multiple-myeloma/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T11:03:50.000Z",
    "summary": "Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma."
  },
  {
    "title": "STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study",
    "link": "https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T10:24:06.000Z",
    "summary": "Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study."
  },
  {
    "title": "Women’s heart attack risk rises even if arteries aren’t as clogged as men’s",
    "link": "https://www.statnews.com/2026/02/23/heart-disease-in-women-plaque-scan-risk/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T10:00:00.000Z",
    "summary": "The smaller arteries of women means a little plaque can be more dangerous than it is for men."
  },
  {
    "title": "Small and mighty: single-domain antibodies pack a biological punch",
    "link": "https://www.biopharmadive.com/spons/small-and-mighty-single-domain-antibodies-pack-a-biological-punch/811314/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T10:00:00.000Z",
    "summary": "VHH antibodies: they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!"
  },
  {
    "title": "STAT+: A provocative proposal asks the FDA to let some AI devices on the market without review",
    "link": "https://www.statnews.com/2026/02/23/harrisonai-fda-petition-exempt-ai-devices-premarket-review/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "A provocative new proposal has offered the FDA a way to let a broad swath of potentially risky AI devices flood the market."
  },
  {
    "title": "STAT+: Health care reform might be a focus in midterms. For Congress, pursuing it will be an uphill climb",
    "link": "https://www.statnews.com/2026/02/23/health-care-reform-midterms-trump/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "Lawmakers will likely have a lot to say about health care this year. Paradoxically, they probably won't accomplish much on the subject."
  },
  {
    "title": "Opinion: No one in health care should be called a ‘provider’",
    "link": "https://www.statnews.com/2026/02/23/provider-ethical-objections-physician-acp/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "The word “provider” in health care turns the relationship between patient and physician into a commercial transaction, argues the American College of Physicians."
  },
  {
    "title": "Grail’s multi-cancer early detection test misses study goal",
    "link": "https://www.biopharmadive.com/news/grails-multi-cancer-early-detection-test-misses-study-goal/812744/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T19:16:43.000Z",
    "summary": "Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses."
  },
  {
    "title": "Supreme Court invalidates Trump tariffs based on emergency powers",
    "link": "https://www.biopharmadive.com/news/supreme-court-invalidates-trump-tariffs-based-on-emergency-powers/812723/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T18:57:00.000Z",
    "summary": "In a 6-3 decision, the court rejected President Trump's claim that a 1977 law gave him the authority to impose broad tariffs globally."
  },
  {
    "title": "Trump sets fresh 10% global tariff — and plans to increase further",
    "link": "https://www.biopharmadive.com/news/trump-vows-new-10-tariff-supreme-court-ruling/812801/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T18:05:00.000Z",
    "summary": "The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%."
  },
  {
    "title": "Roche gets FDA decision date on closely watched breast cancer drug",
    "link": "https://www.biopharmadive.com/news/roche-giredestrant-serd-fda-approval-decision-breast-cancer/812695/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T17:16:22.000Z",
    "summary": "The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors."
  },
  {
    "title": "Clearing cholesterol combats secondary lymphoedema",
    "link": "https://www.nature.com/articles/d41573-026-00032-6",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "The pancreatic cancer drug market",
    "link": "https://www.nature.com/articles/d41573-026-00027-3",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "PIP4K2C: an emerging fulcrum for multiple diseases",
    "link": "https://www.nature.com/articles/d41573-026-00030-8",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-18T00:00:00.000Z",
    "summary": ""
  }
]
